


We Claim:

1. A compound having the structure:



- 5 or any pharmaceutically-acceptable salt thereof, wherein:

L is $-C(R^1)=C(R^2)-$ or $-C(R^2)=C(R^1)-$;

Q^1 is N or $C(R^5)$;

Q^2 is N or $C(R^6)$;

Q^3 is N or $C(R^7)$;

10 Q^4 is N or $C(R^6)$;


X^1 is NH, S, S=O, S(=O)₂ or O;

X^2 is N or $C(R^8)$;

X^3 is N or $C(R^9)$;

Y is NH, $C(R^{10})(R^{11})$, O, S, S(=O), S(=O)₂ or C(=O);

15 R^1 is selected from



R^2 is H, C₁₋₂alkyl, -CF₃, -NH₂, -OH, -OCH₃, F, Cl or Br;

R^3 is halo, C₁₋₆alkyl, C₁₋₄haloalkyl, -N(H)C₁₋₄alkyl, -N(C₁₋₄alkyl)C₁₋₄alkyl or -OC₁₋₄alkyl;

20 R^4 is Br, I, C₂₋₆alkyl, C₁₋₄haloalkyl, -C(=O)R^b, -OR^b, -(C₁₋₄haloalkyl)OH, -N(C₁₋₂alkyl)C₁₋₂alkyl or -CN; wherein if Y is CH₂ and R³ and R⁵ are both Cl, then R⁴ is other than isopropyl;

R^5 is, independently in each instance, H, halo, C₁₋₆alkyl, C₁₋₄haloalkyl, -N(H)C₁₋₄alkyl, -N(C₁₋₄alkyl)C₁₋₄alkyl or -OC₁₋₄alkyl;

25 R^6 is, independently in each instance, H, F, C₁₋₆alkyl, C₁₋₄haloalkyl, -N(R^a)R^a, -OR^a, -S(=O)₂N(R^a)R^a, -C(=O)N(R^a)R^a, or -N(R^a)C(=O)R^b;

R^7 is H, F, C₁₋₆alkyl, C₁₋₄haloalkyl, -N(R^a)R^a, -OR^a, -S(=O)₂N(R^a)R^a, -C(=O)N(R^a)R^a, or -N(R^a)C(=O)R^b;

R^8 is H, halo, C_{1-6} alkyl, C_{1-4} haloalkyl, $-N(H)C_{1-4}$ alkyl, $-N(C_{1-4}$ alkyl) C_{1-4} alkyl or $-OC_{1-4}$ alkyl;

R^9 is H, halo, C_{1-6} alkyl, C_{1-4} haloalkyl, $-N(H)C_{1-4}$ alkyl, $-N(C_{1-4}$ alkyl) C_{1-4} alkyl or $-OC_{1-4}$ alkyl;

5 R^{10} is H, F, C_{1-6} alkyl, C_{1-4} haloalkyl, $-N(R^a)R^a$, or $-OR^a$;

R^{11} is H, F, C_{1-6} alkyl, C_{1-4} haloalkyl, $-N(R^a)R^a$, or $-OR^a$;

R^a is, independently at each instance, H or C_{1-6} alkyl; and

R^b is, independently at each instance, C_{1-6} alkyl.

10 2. A method of treating acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory
15 eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial
20 tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders, comprising the step of administering a compound according to Claim 1.

25

3. A method of treating acute pain, comprising the step of administering a compound according to Claim 1.

30 4. A method of treating inflammatory pain, comprising the step of administering a compound according to Claim 1.

5. A method of treating neuropathic pain, comprising the step of administering a compound according to Claim 1.
 6. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically-acceptable diluent or carrier.
- 5